Tony Godfrey is a professor of surgery and computational biomedicine at Boston University. A co-founder of Gothenburg, Sweden, based SimSen Diagnostics, his research interests include cancer biomarkers and molecular pathology (with a particular focus on technique development and clinical application of novel genomic technologies). Since 2001, he has received continuous funding from the National Institutes of Health for his role as an independent investigator. He is a standing member of the National Cancer Institute’s Cancer Biomarkers Study Section and serves as a peer reviewer for many influential journals. Tony is a member of the scientific advisory boards of the DeGregorio Family Foundation as well as that of Fluent BioSciences (where he guides efforts to evaluate our technologies in oncologic clinical applications), and a past member of the Cepheid scientific advisory board.
He obtained a PhD from London’s Brunel University and completed postdoctoral work at the University of California, San Francisco.